samedan logo

 
 
spacer
home > pmps > winter 2004 > powder flowability – the impact of getting it right
PAY PER VIEW SERVICE

 

Dear guest!

article: Powder Flowability – The Impact of Getting it Right
format: Adobe Acrobat PDF file
cost: £

spacer

 
News and Press Releases

Ubiquigent Obtains Exclusive License for UbiSite Technology to Strengthen its Specialist Drug Discovery Services

Dundee, UK, 31 October 2022: Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitylase (DUB) modulators as new therapeutics for areas of high unmet medical need, has signed an exclusive license with the University of Southern Denmark for its UbiSite® technology. UbiSite will form a new component in Ubiquigent’s DUB and ubiquitin-proteasome system (UPS) focused drug discovery platform, providing a fully supported ubiquitomics service to facilitate target identification, target validation, and compound mechanism of action.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement